IBS (Irritable Bowel Syndrome)
83
15
19
39
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.6%
3 terminated out of 83 trials
92.9%
+6.4% vs benchmark
8%
7 trials in Phase 3/4
5%
2 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (83)
A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
Sucrase-Isomaltase (SI) Genes and Meal Load
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
Prevalence of Disorders of Gut-Brain-Interaction in Pediatric Patients With In-remission Inflammatory Bowel Disease
Personalized Therapy of Long-term Low FODMAP in IBS Treatment: Role of Mobile Application and "Microbiota-gut-brain" Axis
Efficacy of Rifaximin With NAC in IBS-D
Personalised Multidisciplinary Treatment in Moderate to Severe IBS
Gut Microbiome in Patients With Post-infectious Irritable Bowel Syndrome
Ebastine Versus Mebeverine in IBS Patients
Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)
Lactose Intolerance and Intestinal Permability
Relaxation Music for Chronic Pain
Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
Comparison Between Low FODMAP and SSRD in IBS
RCT of VR Therapy for IBS
Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea